TY - JOUR
T1 - Probiotic nanovesicles encapsulating baicalin
T2 - a strategy to overcome colorectal cancer
AU - Li, Yifan
AU - Zhao, Xinrui
AU - Wang, Dan
AU - Wang, Ruilin
AU - Zhu, Rui
AU - You, Xiaojuan
AU - Liu, Xinwei
AU - Li, Yongwei
N1 - This work is kindly supported by the Henan Provincial Postdoctoral Research Funding Project [Grant No.: HN2024091] and the Henan Provincial Science and Technology Research Project [Grant No.: 242102310381].
Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of Applied Microbiology International.
PY - 2025/3
Y1 - 2025/3
N2 - Escherichia coli Nissle 1917 (EcN) is a unique probiotic utilized to treat inflammatory bowel disease and irritable bowel syndrome. Outer membrane vesicles (OMVs) from EcN can not only deliver pro-biotic anti-inflammatory molecules to cancer cells to exert anti-rectal cancer effects, but also deliver therapeutic drugs, genes, and other “cargoes” encapsulated in the vesicles to specific cells, making them an ideal vehicle for drug delivery. In this study, we successfully isolated OMVs of probiotic origin and obtained BCN-OMVs by encapsulating baicalin (BCN) in EcN-OMVs. Fluorescence microscopy showed that both fluorescently labeled EcN-OMVs and BCN-OMVs were able to enter HT-29 cells. The results of CCK-8, plate cloning, flow cytometry, and western blotting indicated that the vitality and proliferation of HT-29 cells were sensibly inhibited after treatment with BCN-OMVs. Additionally, apoptosis-related proteins and proteins involved in the NF-kB pathway were also expressed differently. The results above suggest that EcN-OMVs, serving as a bio-nanocarrier of BCN, can effectively address the limitations of BCN, such as poor water solubility and low bioavailability. They also play a significant anti-tumor role by enhancing cancer cell apoptosis, showing promising potential in targeted therapy for colorectal cancer (CRC).
AB - Escherichia coli Nissle 1917 (EcN) is a unique probiotic utilized to treat inflammatory bowel disease and irritable bowel syndrome. Outer membrane vesicles (OMVs) from EcN can not only deliver pro-biotic anti-inflammatory molecules to cancer cells to exert anti-rectal cancer effects, but also deliver therapeutic drugs, genes, and other “cargoes” encapsulated in the vesicles to specific cells, making them an ideal vehicle for drug delivery. In this study, we successfully isolated OMVs of probiotic origin and obtained BCN-OMVs by encapsulating baicalin (BCN) in EcN-OMVs. Fluorescence microscopy showed that both fluorescently labeled EcN-OMVs and BCN-OMVs were able to enter HT-29 cells. The results of CCK-8, plate cloning, flow cytometry, and western blotting indicated that the vitality and proliferation of HT-29 cells were sensibly inhibited after treatment with BCN-OMVs. Additionally, apoptosis-related proteins and proteins involved in the NF-kB pathway were also expressed differently. The results above suggest that EcN-OMVs, serving as a bio-nanocarrier of BCN, can effectively address the limitations of BCN, such as poor water solubility and low bioavailability. They also play a significant anti-tumor role by enhancing cancer cell apoptosis, showing promising potential in targeted therapy for colorectal cancer (CRC).
KW - baicalin
KW - colorectal cancer
KW - Escherichia coli Nissle 1917
KW - outer membrane vesicles
KW - probiotic
UR - http://www.scopus.com/inward/record.url?scp=105001978262&partnerID=8YFLogxK
U2 - 10.1093/lambio/ovae117
DO - 10.1093/lambio/ovae117
M3 - Journal article
C2 - 39586276
AN - SCOPUS:105001978262
SN - 0266-8254
VL - 78
JO - Letters in Applied Microbiology
JF - Letters in Applied Microbiology
IS - 3
M1 - ovae117
ER -
